Skip to main content
Premium Trial:

Request an Annual Quote

Missed Early Cases

A new analysis suggests SARS-CoV-2 may have been present in parts of the US as early as late December 2019, the New York Times reports. It notes, though, that the study's small sample size may make it difficult to distinguish true and false positives.

 As they report in the journal Clinical Infectious Diseases, the researchers from the US National Institutes of Health's All of Us research project retrospectively tested more than 24,000 blood samples for SARS-CoV-2 antibodies. Of these samples, 147 had a positive result on one test and nine of those also had a positive result on a second antibody test. Seven of these nine samples were from before there were known COVID-19 cases in participants' states, and one collected in early January 2020 in Illinois that indicates the virus may have been present there in late December 2019, as it takes about two weeks for antibodies to develop.

This, the Times notes, is in line with previous analyses suggesting that early cases in the US and elsewhere may have been missed.

"It helps us understand a little bit more about the geographic spread of where the virus was in those very early days of the US epidemic," lead author Keri Althoff from the Johns Hopkins Bloomberg School of Public Health tells the Wall Street Journal.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.